Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1996 May;100(5):524-9.
doi: 10.1016/s0002-9343(95)00059-3.

Redefining the incidence of clinically detectable atheroembolism

Affiliations
Comparative Study

Redefining the incidence of clinically detectable atheroembolism

R R Mayo et al. Am J Med. 1996 May.

Abstract

Background and objectives: Atheroembolism, caused by peripheral embolization of small cholesterol crystals that fracture off of ruptured atherosclerotic plaques in the major vessels, leads to multifocal ischemic lesions and progressive tissue loss. The end result is often ischemic injury in the skin, kidney, brain, myocardium, and intestine, but any organ distal to the culprit lesion may be affected. The precise incidence of this serious clinical syndrome has been difficult to ascertain from the available literature, but it appears to be much more common than has been assumed. The objective of the present study is to clarify the incidence of atheroembolism among inpatients in an acute hospital setting.

Patients and methods: We surveyed inpatient nephrology consultations during a 7-month period from January through July 1994. From a pool of 402 consultation charts, 99 were identified with two or more substantive risk factors for atheroembolism. The records of 85 of these patients were available for careful review. More than 300 additional patients were found to have ICD-9 discharge codes for other vascular conditions, but we were unable to confirm that any of these were in fact cases of atheroembolism, since there is no specific ICD-9 discharge code for this entity. In the 85 cases reviewed, a diagnosis of atheroembolism was made only if the patient had identifiable substantive risk factors, suggestive physical findings, and supporting laboratory results.

Results: Eleven of the 85 surveyed records documented strong evidence supporting a "probable" diagnosis of atheroembolism. Tissue was examined in 4 of these 11, resulting in definitive histologic confirmation in 3. Another 5 of the 85 surveyed records were "suggestive" of atheroembolism. Altogether, atheroembolism was a likely diagnosis in a total of 16 cases during this 7-month period, or 1 case in every 2 weeks. These cases comprised 19% of nephrology consultations in which 2 or more risk factors were present, or 4% or all nephrology consultations. The patients' records confirmed the serious implications of clinically detectable atheroembolism. Several patients underwent lower extremity amputation, nearly half required acute or chronic dialysis, and more than half died within several months of diagnosis

Conclusions: The present study suggests that at least 4% of all inpatient nephrology consultations, representing approximately 5% to 10% of the acute renal failure encountered, involve clinically significant atheroembolism. Patients with atheroembolism appear at a rate of at least 1 case every 2 weeks. They often have identifiable substantive risk factors at initial consultation, and probably represent only the most severe cases of atheroembolism. In view of the serious implications of this basically untreatable syndrome, heightened awareness and preventive maneuvers in the population at risk are essential.

PubMed Disclaimer

Similar articles

Cited by

  • Eosinophilia and Kidney Disease: More than Just an Incidental Finding?
    Gauckler P, Shin JI, Mayer G, Kronbichler A. Gauckler P, et al. J Clin Med. 2018 Dec 8;7(12):529. doi: 10.3390/jcm7120529. J Clin Med. 2018. PMID: 30544782 Free PMC article. Review.
  • A man with purple toes.
    Zaman S, Mallya J, Thomas M. Zaman S, et al. Postgrad Med J. 1998 Jan;74(867):51-5. doi: 10.1136/pgmj.74.867.51. Postgrad Med J. 1998. PMID: 9538493 Free PMC article. No abstract available.
  • Atheroembolism.
    Smyth JS, Scoble JE. Smyth JS, et al. Curr Treat Options Cardiovasc Med. 2002 Jun;4(3):255-265. doi: 10.1007/s11936-002-0006-4. Curr Treat Options Cardiovasc Med. 2002. PMID: 12003724
  • Lesson of the week: cholesterol emboli syndrome.
    Dupont PJ, Lightstone L, Clutterbuck EJ, Gaskin G, Pusey CD, Cook T, Warrens AN. Dupont PJ, et al. BMJ. 2000 Oct 28;321(7268):1065-7. doi: 10.1136/bmj.321.7268.1065. BMJ. 2000. PMID: 11053182 Free PMC article. No abstract available.
  • Cholesterol-embolization syndrome: current perspectives.
    Ozkok A. Ozkok A. Vasc Health Risk Manag. 2019 Jul 8;15:209-220. doi: 10.2147/VHRM.S175150. eCollection 2019. Vasc Health Risk Manag. 2019. PMID: 31371977 Free PMC article. Review.

Publication types

LinkOut - more resources